Relieves inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. ANDA 89795, held by Cosette Pharms Nc. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 89795 (Triamcinolone Acetonide), held by Cosette Pharms Nc, was first approved by FDA on Dec 23, 1988, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 23, 1988 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.025% · ointment;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
